Moderna-Merck mRNA Vaccine Cuts Melanoma Recurrence Risk by 42%

Moderna-Merck mRNA Vaccine Cuts Melanoma Recurrence Risk by 42%

Business Health
Sign in to pin this event

Moderna and Merck said their personalized mRNA vaccine intismeran, given with Keytruda, reduced melanoma recurrence or death by 42% in a phase-3 trial. The finding was echoed in reports from Ars Technica, BioPharma Dive and NBC News, which also noted that both companies' shares fell after the announcement.

Actors

Moderna Merck TD Cowen RBC Capital Markets

Locations

Wall Street, New York, United States

Fact Check

How these metrics work
Verdict: Partially confirmed Confidence: 73% Claims: 5
At a glance

All five claims analyzed were partially confirmed. The claim that Merck and Moderna reported their personalized mRNA vaccine combined with Keytruda reduced the risk of death or recurrence by 42% in patients with resected melanoma on October 22, 2026, was partially confirmed. The October 23, 2026, claim about the phase III study where the Moderna-Merck vaccine intismeran reduced melanoma recurrence and death by 42% when added to Keytruda, compared to Keytruda alone, was partially confirmed. The claim dated October 25, 2026, stating that a Merck-Moderna mRNA vaccine combined with Keytruda lowered melanoma recurrence or death by 42% in a pivotal study was partially confirmed. The October 26, 2026, claim about a phase 3 study showing a 42% reduction in melanoma recurrence or death with the personalized mRNA vaccine developed by Moderna and Merck versus standard immunotherapy alone was partially confirmed. Finally, the October 22, 2026, claim that the combined vaccine and Keytruda regimen lowered distant metastasis risk by 38% in melanoma patients was also partially confirmed.

Sign in or subscribe to unlock the full breakdown: claims, sources, and validations.

Sign up Sign in

This section contains an automated verification of claims against external sources and may contain inaccuracies.

Articles

October 26, 2026
1 total
Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk by 42% in Phase 3 Trial
Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk by 42% in Phase 3 Trial

ScienceAlert • 26 Oct 02:01

A phase 3 study of a personalized mRNA vaccine developed by Moderna and Merck showed a 42% reduction in melanoma recurrence or death compared with standard immunotherapy alone.

Credibility 78% Manip. 32% Center
October 25, 2026
2 total
Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in trial
Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in trial

The Globe and Mail • 25 Oct 18:12

A trial of the mRNA-based vaccine intismeran showed a 42% reduction in melanoma recurrence two years after surgery when added to standard therapy.

Credibility 78% Manip. 12% Center
Custom mRNA Vaccine Cuts Melanoma Recurrence Risk in Trial
Custom mRNA Vaccine Cuts Melanoma Recurrence Risk in Trial

STAT • 25 Oct 08:34

A Merck-Moderna mRNA vaccine combined with Keytruda lowered melanoma recurrence or death by 42% in a pivotal study, prompting discussion of broader cancer-vaccine applications.

Credibility 73% Manip. 32% Center
October 23, 2026
1 total
Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in late-stage trial
Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in late-stage trial

NBC News • 23 Oct 18:42

In a phase III study, the Moderna-Merck personalized mRNA vaccine intismeran reduced melanoma recurrence and death by 42% when added to Keytruda, compared with Keytruda alone.

Credibility 71% Manip. 32% Center
October 22, 2026
2 total
Moderna-Merck melanoma vaccine cuts relapse risk by 42% but shares dip
Moderna-Merck melanoma vaccine cuts relapse risk by 42% but shares dip

BioPharma Dive • 22 Oct 22:24

A combined vaccine and Keytruda regimen reduced the relative risk of disease recurrence or death by 42% in advanced melanoma, meeting expectations, while the companies' stocks fell after the announcement.

Credibility 71% Manip. 8% Center
Personalized mRNA vaccine cuts melanoma recurrence and death risk by 42% in Phase 3 trial
Personalized mRNA vaccine cuts melanoma recurrence and death risk by 42% in Phase 3 trial

Ars Technica • 22 Oct 22:12

Merck and Moderna reported that their personalized mRNA vaccine combined with Keytruda reduced the risk of death or recurrence by 42% in patients with resected melanoma, and lowered distant metastasis risk by 38%.

Credibility 78% Manip. 7% Center

Related events